Viridian Therapeutics share price logo

Viridian Therapeutics

NASDAQ: VRDN

Mid Cap

$22.83

+0.05

(+0.22%)

Live

as on

Viridian Therapeutics Stock Performance

as on September 4, 2026 at 2:10 am IST

  • Day's Low

    Day's High

    $22.63
    $23.28
    downward going graph

    0.88%

    Downside

    1.97%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $13.18
    $34.29
    downward going graph

    42.27%

    Downside

    50.20%

    Upside

    downward going graph

Viridian Therapeutics share price movements today

Previous Close
$22.78
Open
$23.28
Volume
101.7K
Market Cap
$2.6B
Day's Low - High
$22.63 - $23.28
52 Week Low - High
$13.18 - $34.29

Viridian Therapeutics Historical Returns

1 Month Return
+ 21.72 %
3 Month Return
+ 45.12 %
1 Year Return
+ 20.32 %
3 Year Return
+ 20.51 %
5 Year Return
+ 82.49 %

Viridian Therapeutics Stock Fundamentals & Key Indicators

Check Viridian Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$2.6B

EPS (TTM)

-3.53

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-6.23

Industry PE ratio

-13.558214285714286

PEG Ratio

-0.6909653204764195

EBITDA

-368.1M

Revenue (TTM)

71.1M

Profit Margin

99.38%

Return On Equity TTM

-61.35%

Viridian Therapeutics Stock Valuation

Track how Viridian Therapeutics P/E has moved over time to understand its valuation trends.

Viridian Therapeutics in the last 5 years

  • Overview

  • Trends

Lowest (-9.37x)

December 31, 2025

Industry (-13.56x)

December 31, 2025

Today (-9.37x)

December 31, 2025

Highest (-2.97x)

December 31, 2021

LowHigh

Today’s Price to Earnings Ratio: -9.37x

Viridian Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Viridian Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$2.6B82.49%-6.2399.38%NA
BUY$44.6B614.61%NA0.00%NA
BUY$137.9B174.9%31.9286.04%NA
BUY$61.6B-61.21%-7.98-12.57%NA
BUY$82.3B21.91%19.984.86%0.44%

Stock Returns calculator for Viridian Therapeutics Stock including INR - Dollar returns

The Viridian Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Viridian Therapeutics investment value today

Current value as on today

₹1,27,949

Returns

₹27,949

(+27.95%)

Returns from Viridian Therapeutics Stock

₹19,279 (+19.28%)

Dollar Impact

₹8,670 (+8.67%)

Analyst Recommendation on Viridian Therapeutics Stock

Based on 13 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 13 analysts, 100% of analysts recommend a 'BUY' rating for Viridian Therapeutics. Average target price of $36.62

Viridian Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Viridian Therapeutics.

What analysts predicted

37.66%UPSIDE

Target Price

$36.62

Current Price

$22.83

Analyzed by

13 Analysts

Target

$36.62

Viridian Therapeutics target price $36.62, a slight upside of 37.66% compared to current price of $22.83. According to 13 analysts rating.

Indian Investors' Interest in Viridian Therapeutics Stock

Search interest for Viridian Therapeutics Stock has decreased by -43% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-43% versus previous 30 day period

Viridian Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
0
0
0
0
0
0
70
0
0
0
Gross Profit
0
0
0
0
0
0
70
0
0
0
Operating Income
-55
-72
-83
-87
-93
-106
-40
-122
-116
-126
EBITDA
-47
-64
-75
-78
-86
-100
-33
-114
-101
-118
Interest Expense
0
0
1
0
0
0
0
6
3
8
Depreciation
0
0
0
0
0
0
0
0
0
-
Income Before Tax
-48
-64
-76
-79
-86
-100
-34
-120
-104
-127
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-48
-64
-76
-79
-86
-100
-34
-120
-104
-127
Net Profit Margin
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
-142.42%
14.18%
100.00%

Viridian Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
4
8
4
1
2
1
0
0
70
Gross Profit
-15
-22
4
-27
2
1
0
0
70
Operating Income
-26
-33
-41
-110
-79
-134
-254
-299
-363
EBITDA
-25
-31
-40
-40
-79
-129
-235
-265
-337
Interest Expense
0
0
0
0
0
0
1
3
4
Depreciation
0
0
0
0
0
0
0
1
0
Income Before Tax
-26
-32
-41
-110
-79
-129
-237
-269
-342
Income Tax Expense
0
-
-
-
-
-
-
-
-
Net Income
-26
-32
-41
-110
-79
-129
-237
-269
-342
Net Profit Margin
-390.21%
-262.76%
100.00%
-2595.62%
100.00%
100.00%
100.00%
100.00%
100.00%

Viridian Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-48
-64
-76
-79
-86
-100
-34
-120
-104
-127
Operating Cash Flow
-45
-46
-67
-73
-92
-75
-84
-23
-119
-105
Investing Cash Flow
-143
61
-84
-62
100
75
126
-339
77
-231
Financing Cash Flow
177
0
245
35
9
0
10
405
6
325
Change in Cash
-11
16
92
-100
16
1
52
42
-36
-11

Viridian Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-26
-32
-41
-110
-79
-129
-237
-269
-342
Operating Cash Flow
-28
-26
-36
-29
-54
-93
-184
-232
-276
Investing Cash Flow
1
-29
28
-50
-74
-115
-94
-228
-37
Financing Cash Flow
52
41
0
101
125
322
225
457
426
Change in Cash
25
-14
-7
21
-3
113
-52
-3
112

Mutual Funds that own Viridian Therapeutics Stock

Check out the Mutual Funds with significant holdings in Viridian Therapeutics.

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
3.588192%
4065145
Fidelity Select Portfolios
3.372431%
3820704
Fidelity Securities Fund
2.504323%
2837205
Fidelity Advisor Series VII
2.33243%
2642464
Fidelity Concord Street Trust
1.16181%
1316241

Global Institutional Holdings in Viridian Therapeutics

Funds
Holdings
Vanguard
4.7%
Peter Harwin
4.49%
SPDR
3.99%
iShares
3.55%
Felix Baker
2.1%

Viridian Therapeutics News & Key Events

  • img

    Today's Timeline - 29 June

    Mon, 06:54 PM

    -

    FDA approves Viridian's Lumvoa for thyroid eye disease, marking a significant milestone for the company.

Insights on Viridian Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, VRDN stock has moved up by 39.3%

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 3 quarters, 132.0K → 284.0K (in $), with an average increase of 28.4% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 527.1% return, outperforming this stock by 510.1%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 34.0% return, outperforming this stock by 14.8%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -104.90M → -127.11M (in $), with an average decrease of 21.2% per quarter

About Viridian Therapeutics

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.
OrganisationViridian Therapeutics
Headquarters221 Crescent Street, Waltham, MA, United States, 02453
IndustryBiotechnology
CEOMr. Stephen F. Mahoney J.D., MBA
E-voting on sharesClick here to vote

Key Management of Viridian Therapeutics

Name

Title

Mr. Thomas W. Beetham J.D., MBA

Chief Operating Officer

Dr. Michael R. Bristow M.D., Ph.D.

Co-Founder & Member of the Scientific Advisory Board

Dr. Marvin H. Caruthers Ph.D.

Co-Founder & Scientific Advisory Board Member

Mr. Vahe Bedian Ph.D.

Co-Founder & Scientific Advisor

Ms. Melissa Manno

Chief Human Resources Officer

Mr. Stephen F. Mahoney J.D., MBA

CEO, President & Director

Mr. Seth Harmon

Chief Financial Officer

Dr. Eric N. Olson Ph.D.

Co-Founder & Chairman of Scientific Advisory Board

Ms. Jennifer Tousignant J.D.

Chief Legal Officer & Corporate Secretary

Dr. Radhika Tripuraneni M.D., M.P.H.

Chief Medical Officer

FAQs

What is Viridian Therapeutics share price today?

Viridian Therapeutics share price today is $22.83 as on . Viridian Therapeutics share today touched a day high of $23.28 and a low of $22.63.

What is the 52 week high and 52 week low for Viridian Therapeutics share?

Viridian Therapeutics share touched a 52 week high of $34.29 on and a 52 week low of $13.18 on . Viridian Therapeutics stock price today i.e. is trending at $22.83,which is 33.42% down from its 52 week high and 73.22% up from its 52 week low.

What is Viridian Therapeutics's market capitalisation today?

Viridian Therapeutics market capitalisation is $0.00T as on .

How to invest in Viridian Therapeutics Stock (VRDN) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Viridian Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Viridian Therapeutics Shares that will get you 0.0657 shares as per Viridian Therapeutics share price of $22.83 per share as on September 3, 2026 at 8:40 pm IST.

What is the minimum amount required to buy Viridian Therapeutics Stock (VRDN) from India?

Indian investors can start investing in Viridian Therapeutics (VRDN) shares with as little as ₹94.475 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹944.75 in Viridian Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Viridian Therapeutics share’s latest price of $22.83 as on September 3, 2026 at 8:40 pm IST, you will get 0.4380 shares of Viridian Therapeutics. Learn more about fractional shares .

What are the returns that Viridian Therapeutics has given to Indian investors in the last 5 years?

Viridian Therapeutics stock has given 82.49% share price returns and 30.37% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?